Chiron pharma research
Executive Summary
Pharmacia VP-Discovery Oncology Kenneth Bair, MD, joins Chiron as senior VP-BioPharma research head, effective July 1. He will oversee chemistry, biology, applied biochemistry and discovery projects, and "work with the research head of Chiron's Vaccines and Blood Testing business units to promote organizational synergies," Chiron says. Chiron acquired the vaccine manufacturer Powderject in May (1"The Pink Sheet" May 26, 2003, p. 17). Invenux CEO Carl Pelzel joins Chiron as VP-BioPharma commercial operations...
You may also be interested in...
Chiron Vaccines Get Shot In The Arm With PowderJect Needleless Technology
Chiron will gain access to PowderJect's needleless vaccine technology and a platform through which to launch vaccines in the U.S. with its $878 mil. acquisition of the Fluvirin manufacturer
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.